Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors

International Journal of Urology

Volumn 11, Issue 6, 2004, Pages 407-415

  Saga, Yuji ^a   Hashimoto, Hiroshi ^a   Yachiku, Sunao ^a   Iwata, Tatsuya ^a   Tokumitsu, Masayuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Acquired resistance; Biochemical modulation; Cisplatin; Metallothionein; Propargylglycine

Indexed keywords

CISPLATIN; CYSTATHIONINE GAMMA LYASE; METALLOTHIONEIN; PLATINUM DERIVATIVE; PROPARGYLGLYCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

ALKYNES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CYSTATHIONINE GAMMA-LYASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GLUTATHIONE; GLYCINE; INJECTIONS, INTRAPERITONEAL; METALLOTHIONEIN; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; URINARY BLADDER NEOPLASMS;

EID: 3042702891     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00803.x     Document Type: Article

References (34)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-6.
2. Merrin CE. Treatment of genitourinary tumours with cis- dichlorodiammineplatinum (II): Experience in 250 patients. Cancer Treat. Report 1979; 63: 1579-84.
3. Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK. Cisplatin: An active drug in the treatment of disseminated gastric cancer. Cancer 1984; 53: 18-22.
4. Einhorn LH. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 1990; 8: 1777-81.
5. Barker GH, Wiltshaw E. Use of high dose cis-dichlorodiammineplatinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br. J. Obstet. Gynaecol. 1981; 88: 1192-9.
6. Pont J, Bokemeyer C, Harstrick A, Sellner F, Greinix H, Stoiber F. Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support. A retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann. Oncol. 1997; 8: 1229-34.
7. Andrews PA, Velury S, Mann SC, Howell SB. Cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res. 1988; 48: 68-73.
8. Bungo M, Fujiwara Y, Kasahara K et al. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: Relation to DNA damage and repair. Cancer Res. 1990; 50: 2549-53.
9. Fujii R, Mutoh M, Niwa K, et al. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J. Cancer Res. 1994; 85: 426-33.
10. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer 1991; 64: 215-20.
11. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992; 52: 6885-9.
12. Bakka A, Endresen L, Johnsen AB, Edminson PD, Rugstad HE. Resistance against cis-dichlorodiammine-platinum in cultured cells with a high content of metallothionein. Toxicol. Appl. Pharmacol. 1981; 61: 215-16.
13. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-15.
14. Yokomizo A, Ono M, Nanri H et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 1995; 55: 4293-6.
15. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 1988; 48: 5713-16.
16. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat. Res. 2001; 478: 23-43.
17. Cherian MG, Goyer RA. Methallothioneins and their role in the metabolism and toxicity of metals. Life Sci. 1978; 23: 1-9.
18. Karin M. Metallothioneins: proteins in search of function. Cell. 1985; 41: 9-10.
19. Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J. Pharmacol. Exp. Ther. 1995; 275: 1681-7.
20. Siegsmund MJ, Marx C, Seemann O et al. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol. Res. 1999; 27: 157-63.
21. Okazaki Y, Miura N, Satoh M, Imura N, Naganuma A. Metallothionein- mediated resistance to multiple drugs can be induced by several anticancer drugs in mice. Biochem. Biophys. Res. Commun. 1998; 245: 815-18.
22. Abeles RH, Walsh CT. Acetylenic enzyme inactivators. Inactivation of gamma-cystathionase, in vitro and in vivo, by propargylglycine. J. Am. Chem. Soc. 1973; 95: 6124-5.
23. Gallant KR, Cherian MG. Metabolic changes in glutathione and metallothionein in newborn rat liver. J. Pharmacol. Exp. Ther. 1989; 249: 631-7.
24. Satoh M, Kloth DM, Kadhim SA. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res. 1993; 53: 1829-32.
25. Soloway MS. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res. 1977; 37: 2918-29.
26. Scheuhammer AM, Cherian MG. Quantification of metallothionein by the silver saturation. Meth. Enzymol. 1991; 205: 78-83.
27. Kagi JH. Overview of metallothionein. Meth. Enzymol. 1991; 205: 613-26.
28. Farnworth PG, Hillcoat BL, Roos IA. Metallothionein induction in mouse tissues by cis-dichlorodiammine-platinum (II) and its hydrolysis products. Chem. Biol. Interact. 1989; 69: 319-32.
29. Singh G, Koropatnick J. Differential toxicity of cis and trans isomers of dichlorodiammineplatinum. J. Biochem. Toxicol. 1988; 3: 223-33.
30. Endresen L, Schjerven L, Rugstad HE. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum. Acta. Pharmacol. Toxicol. 1984; 55: 183-7.
31. Yamagata K, Kondo Y. A study on the relationship between sensitivity to CDDP and inducibility of metallothionein and glutathione of genitourinary tumors. Nippon Hinyokika Gakkai Zasshi 1995; 86: 1575-82.
32. Zelazowski AJ, Garvey JS, Hoeschele JD. In vivo and in vitro binding of platinum to metallothionein. Arch. Biochem. Biophys. 1984; 229: 246-52.
33. Zhang B, Huang H, Tang W. Interaction of cis- and trans- diamminedichloroplatinum with metallothionein in vivo. J. Inorg. Biochem. 1995; 58: 1-8.
34. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res. 1994; 54: 5255-7.